The latest update is out from Aclarion, Inc. ( (ACON) ).
On February 28, 2025, Aclarion, Inc. adjourned its Special Meeting of Stockholders without conducting any business, with plans to reconvene on March 5, 2025. The adjournment was intended to solicit additional votes on proposals outlined in the company’s proxy statement, emphasizing the importance of shareholder participation in the upcoming meeting.
More about Aclarion, Inc.
Aclarion, Inc. is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), artificial intelligence, and a proprietary biomarker to optimize clinical treatments for low back and neck pain. The company is focused on addressing the $134.5 billion U.S. market for these conditions and is exploring the use of AI and machine learning to enhance data analysis and clinical outcomes.
YTD Price Performance: -94.55%
Average Trading Volume: 419,345
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.67M
Learn more about ACON stock on TipRanks’ Stock Analysis page.